The RCT Ventures program is the vehicle through which Research Corporation Technologies invests in start-up or early-stage companies with technologies that promise patented biomedical products with a clear competitive advantage.
RCT has assets of more than $200 million to advance technology development through flexible, long-term investment options. Our initial financial commitment to our portfolio companies usually ranges from several hundred thousand dollars to several million dollars, and we reserve additional funds for the subsequent funding of successful companies. We can also invest management resources if needed.
Current Areas of Interest
Our current interests include new life-sciences platforms and tools, early-stage therapeutics, and medical devices in the areas of:
- Autoimmune disorders
- Cancer and supportive care
- Cardiovascular diseases
- Dermatologic disorders
- Diabetes & metabolic diseases
- Drug Discovery
- Gastrointestinal disorders
- Neurologic disorders
- Ophthalmological diseases
- Pulmonary disorders
Our current portfolio companies in the United States, Canada, Australia and the United Kingdom are developing a variety of innovative platforms, drugs, diagnostics and devices to help meet these worldwide healthcare needs.
Tell Us About Your Company
If your company meets our criteria and needs further development and commercialization, we would like to hear from you. Please contact us to begin a confidential review of your opportunity.